RELAPSED OR REFRACTORY PLASMA CELL NEOPLASMS
Clinical trials for RELAPSED OR REFRACTORY PLASMA CELL NEOPLASMS explained in plain language.
Never miss a new study
Get alerted when new RELAPSED OR REFRACTORY PLASMA CELL NEOPLASMS trials appear
Sign up with your email to follow new studies for RELAPSED OR REFRACTORY PLASMA CELL NEOPLASMS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New dual-target CAR-T therapy takes on hard-to-treat plasma cell cancers
Disease control Recruiting nowThis early-phase study tests a new treatment called CAR BCMA-CD70 CAR-T for people with high-risk plasma cell neoplasms, a type of blood cancer. The therapy uses the patient's own immune cells, modified to target two cancer markers (BCMA and CD70), to attack the disease. The main…
Matched conditions: RELAPSED OR REFRACTORY PLASMA CELL NEOPLASMS
Phase: EARLY_PHASE1 • Sponsor: Affiliated Hospital to Academy of Military Medical Sciences • Aim: Disease control
Last updated Jul 15, 2026 00:00 UTC
-
Experimental Dual-Target CAR-T therapy takes aim at Hard-to-Treat plasma cell cancers
Disease control Recruiting nowThis early-phase trial is testing a new type of gene therapy called CAR 70-BCMA dual-target CAR-T for people with relapsed or refractory plasma cell neoplasms, including multiple myeloma. The therapy involves taking a patient's own immune cells, re-engineering them to recognize a…
Matched conditions: RELAPSED OR REFRACTORY PLASMA CELL NEOPLASMS
Phase: EARLY_PHASE1 • Sponsor: The General Hospital of Western Theater Command • Aim: Disease control
Last updated Jun 27, 2026 13:05 UTC